AdvisorShares Psychedelics ETF
PSIL - ETF AI Analysis
Top Page
AdvisorShares Psychedelics ETF (PSIL)
PSIL’s rating suggests it is a specialized, higher-risk ETF focused on psychedelics and related biotech, with quality partially supported by established pharma names like Neurocrine, Johnson & Johnson, Eli Lilly, and AbbVie that bring stronger financial performance and more stable growth prospects. However, large positions in early-stage biotech companies such as Mind Medicine, Compass Pathways, Cybin, Relmada, and Bright Minds Biosciences, all facing zero or minimal revenue and ongoing losses, weigh on the fund’s overall quality. The main risk is its heavy concentration in speculative, clinical-stage psychedelics companies, which makes the ETF more volatile and dependent on successful trial outcomes and future financing.
PSIL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 43.26M
- Region
- Global
- Expense Ratio
- 1.00%
- Beta
- 0.90
- Issuer
- AdvisorShares
- Inception Date
- Sep 15, 2021
- Dividend Yield
- 9.36%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
PSIL Summary
The AdvisorShares Psychedelics ETF (PSIL) is a health care fund that focuses on companies developing psychedelic-based treatments for mental health issues like depression and anxiety. It doesn’t track a traditional index, but instead follows the theme of pharma, biotech, and life sciences firms working on these new therapies. Well-known holdings include Eli Lilly and Johnson & Johnson, alongside smaller, more experimental drug makers. Someone might invest for the potential long-term growth of new medical breakthroughs and added diversification. However, this ETF is risky because it holds many young, volatile biotech companies, so its price can swing sharply up or down.
How much will it cost me?
This ETF has an expense ratio of 1.00%, which means you’ll pay about $10 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed and focuses on a very specialized niche in psychedelics and biotech, which typically costs more to run.
What would affect this ETF?
This ETF could benefit if mental health treatments using psychedelics gain wider medical approval, large drug companies keep investing in this area, and global health care spending remains strong. On the other hand, it could be hurt by strict or changing drug regulations, setbacks in clinical trials, shifts in government health policies, or a downturn in biotech stocks worldwide.
PSIL Top 10 Holdings
PSIL is a niche, globally focused health care ETF that leans heavily into early-stage psychedelic drug developers, with COMPASS Pathways and Definium Therapeutics setting the tone. COMPASS has been mixed lately, while Definium is rising this year but still volatile, reflecting the boom-or-bust nature of the space. Relmada and Bright Minds are clearly lagging, acting like weights on the portfolio as their high-risk pipelines struggle to gain traction. Big pharma names like Eli Lilly and Johnson & Johnson provide a steadier backbone, helping balance out the fund’s speculative core.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 DFTX | Definium Therapeutics | 12.12% | $5.28M | $4.74B | 176.20% | 40Neutral |
 CMPS | COMPASS Pathways | 10.35% | $4.50M | $1.31B | 63.16% | 47Neutral |
 TSE:CYBN | Cybin | 8.20% | $3.57M | ― | ― | 37Underperform |
 LLY | Eli Lilly & Co | 6.47% | $2.82M | $1.35T | 45.38% | 72Outperform |
 RLMD | Relmada Therapeutics | 6.54% | $2.85M | $455.48M | 34.65% | 41Neutral |
 ABBV | AbbVie | 5.74% | $2.50M | $519.48B | 31.00% | 66Neutral |
 NBIX | Neurocrine | 5.99% | $2.61M | $17.12B | 18.41% | 80Outperform |
 SPTX | Seaport Therapeutics, Inc. | 5.11% | $2.22M | $1.18B | 7.41% | ―― |
 STIM | Neuronetics | 3.72% | $1.62M | $156.23M | -26.36% | 41Neutral |
 JNJ | Johnson & Johnson | 4.66% | $2.03M | $675.92B | 44.67% | 78Outperform |
PSIL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSIL, the sentiment is Negative. The current price of 20.07 is below the 20-day moving average (MA) of 20.33, below the 50-day MA of 22.12, and below the 200-day MA of 20.82, indicating a bearish trend. The MACD of -0.62 indicates Negative momentum. The RSI at 44.73 is Neutral, neither overbought nor oversold. The STOCH value of 45.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PSIL.
PSIL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| PSIL | $20.07 | $20.50(2.14% Upside) | $43.26M | 1.00% | 44Neutral |
 HRTS | $39.41 | $45.92(16.52% Upside) | $58.37M | 0.75% | 67Neutral |
 OZEM | $31.73 | $49.19(55.02% Upside) | $58.23M | 0.59% | 57Neutral |
 MEDI | $36.25 | $46.16(27.32% Upside) | $44.19M | 0.80% | 62Neutral |
 TMED | $35.44 | $58.28(64.45% Upside) | $39.43M | 0.44% | 59Neutral |
 FMED | $32.76 | ― | $30.30M | 0.50% | 59Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PSIL | AdvisorShares Psychedelics ETF | 20.07 | 4.05 | 25.27% | |
| HRTS | Tema Cardiovascular and Metabolic ETF | 39.41 | 5.54 | 16.35% | |
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 31.73 | 0.20 | 0.64% | |
| MEDI | Harbor Health Care ETF | 36.25 | 5.06 | 16.22% | |
| TMED | T. Rowe Price Health Care ETF | 35.44 | 6.45 | 22.25% | |
| FMED | Fidelity Disruptive Medicine ETF | 32.76 | 5.63 | 20.77% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.